Beam Therapeutics Inc.
BEAMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBeam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. At a $3.06B market cap, Beam Therapeutics Inc. ranks as a mid-cap company within healthcare. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Market Cap
$3.06B
Beta
2.23
P/E (TTM)
—
P/E (Fwd)
-6.26
EPS (TTM)
$-0.69
EPS (Fwd)
$-4.74
ROE
-8.2%
ROA
-17.0%
Cash
$1.15B
Total Debt
$247.4M
Free CF
-$241.8M
52W Change
48.8%
Annual Financials
Cash vs Debt
Where BEAM stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, BEAM finished 0.87% above its 150-day moving average ($28.77) and 2.15% above its 200-day moving average ($28.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BEAM overbought or oversold?
At the September 2, 2026 close, BEAM's RSI(14) was 59.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.15B in cash comfortably exceeding the $247.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$241.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -8.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $60.9M (2022) to $139.7M (2025), reflecting a 129% increase over the period.
With a beta above 1.5, BEAM tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Beam Therapeutics Inc.'s trajectory.